Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, The synthetic Glucocorticoid Methylprednisolone (MP) decreases insulin sensitivity, mucosal immunity and enhances endotoxaemia via down regulation of Interleukin-22, 27/October/2014, 21,06, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: An insight into how Methylprednisolone (MP) decreases insulin sensitivity, mucosal immunity; and increases endotoxaemia.
Significance: This study suggests, for the first time, that Methylprednisolone (MP), by decreasing the expression of IL-22, it may decrease insulin sensitivity, gut immunity; and increase endotoxaemia. Together, this study cautions the long term side effects of using this drug in the treatment of a number of diseases conditions.